Endocrinology

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

This episode covers recent approvals and updated indications allowing more treatment options for children with diabetes.

Crinecerfont enabled sustained GC dose reductions over 2 years, with nearly 70% of adults with classic CAH reaching physiologic dosing.

Gafni discusses the primary results of the phase 3 CALIBRATE trial, testing the investigational oral calcilytic in this difficult-to-treat disease state.

Erika Lundgrin, MD, discusses her recent work comparing the various components of financial toxicity, determining what has the greatest effect on negative outcomes.

Shipra Patel, MD, MS, discusses her recent study highlighting best practices for phase 1 and 2 obesity trials to avoid attrition and loss of data.

Bharat Saboo, MS, discusses his recent study investigating the LLM device in improving both physical and psychological issues associated with T1D.

Samuel Shangwu Wu, PhD, discusses his recent work evaluating TMRCP as an effective endpoint for future T1D trials.

Two-year CAHtalyst data show crinecerfont sustained glucocorticoid reduction and improved metabolic outcomes in classic CAH.

Elena Christofides, MD, discusses her recent analysis of patients with ulcerative colitis receiving corticosteroids.

Baseline characteristics, including sex and comorbidities, were associated with semaglutide weight loss outcomes in >36,000 adults.

Fezolinetant's CNS safety Profile Reassures Across More Than 3,000 Women in Pooled Phase 3 Analysis at ENDO 2026

Elena Christofides, MD, discusses the interim results of CAPTAIN-T2D, a trial that plans to evaluate clofutriben’s efficacy in these patients.

Elif Oral, MD, discusses the clinical implications of the recent data emphasizing metreleptin’s anti-drug antibodies and their llack of impact on efficacy.

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity.

Elif Oral, MD, discusses her recent presentation at ENDO 2026 covering a phase 4 trial of the immunogenicity of metreleptin in this rare disease.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

At ENDO 2026, persistent symptoms in hypothyroidism may reflect non-thyroid causes, underscoring the need for broader clinical evaluation

At ENDO 2026, persistent fatigue and brain fog despite normal thyroid labs underscored the need for individualized care.

Greater BMI reduction with semaglutide in adolescents with severe obesity was tied to improved triglycerides, TG/HDL ratio, and HbA1c

Analysis of plasma EVs identified 448 proteins associated with islet autoimmunity and potential early T1D biomarkers.

Alan Hutchison, MD, PhD, and Mishal Ali discuss the substantially increased risk of long-term mortality caused by diabetes in patients undergoing major organ transplants.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.